^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Endometrial Adenocarcinoma |
| Drug: | azenosertib (ZN-c3) (WEE1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Zentalis Pharmaceuticals Announces Fast Track Designation Granted by the U.S. FDA to ZN-c3 for the Treatment of Uterine Serous Carcinoma
Published date:
11/17/2021
Excerpt:
Zentalis...today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ZN-c3, the Company’s oral WEE1 inhibitor product candidate, for the treatment of recurrent or persistent uterine serous carcinoma (USC) in adult women.
